ClinicalTrials.gg
RecruitingNCT06125340PRESTO-2Updated Dec 12, 2024

Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Short-course Therapy

A Phase 4 interventional study of Placebo and Amoxicillin in Community-acquired Pneumonia, sponsored by Jeffrey. Recruiting at 1 site in Canada. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by Jeffrey · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
6 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Community-Acquired Pneumonia with a site in Canada — 7 open to participants now, 7 under way, 4 of them phase 3. Community-Acquired Pneumonia · Canada.

Planned enrollment
10th of 11
75 · median 219
Started
2024
with 1 other
Phase 4
3 of 15
1 open now
Registered
13th of 15
by date
Lead sponsor
1 of 15
Jeffrey

Among the 15 studies in Community-Acquired Pneumonia with a site in Canada, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 4, and was the 13th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

7 of the 15 studies in Community-Acquired Pneumonia with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 6 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Community-Acquired Pneumonia with a site in Canada, or all of them as a file.
02

Study summary

Children are commonly hospitalized because of community-acquired pneumonia (CAP). There are multiple high-quality randomized trials of short-course antibiotic therapy (3-5 days of treatment) for adults hospitalized with CAP - but there is very little evidence in children. We intend to do a pilot RCT of short-course (3-5 days) vs standard-duration (8-10 days) antibiotic therapy for children hospitalized for CAP.

03

Conditions studied

  • Community-acquired Pneumonia
04

Who can participate

Ages eligible
6 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • children with a history of fever who are hospitalized with CAP (ie. 'severe CAP') as per the clinical team and who have abnormal chest imaging (eg. radiograph, ultrasound) will be eligible. They must also have at least one of the following:

      1. documented tachypnoea (>60 bpm for age \<1 y, >50 bpm for 1-2 y, >40 bpm for 2-4 y, and >30 bpm for >4 y);
      2. cough on exam or by history;
      3. increased work of breathing on exam; or
      4. auscultatory findings (eg. focal crackles, bronchial breathing) consistent with CAP.

Exclusion criteria

Exclusion Criteria:

  • Children will be excluded if: antibiotics have been discontinued; they received >3 days of effective antibiotic treatment (excluding macrolide treatment) prior to hospitalization; there is supplemental oxygen use or fever within the past 24 h; more than 5 days elapsed since admission; the attending clinical team does not wish to use oral amoxicillin for treatment (because of allergy or any other reason); or the child is taking coumadin-based anticoagulants or tetracycline-type antibiotics (because of potential interactions with amoxicillin). Children will also be excluded if they have any of the following: chronic lung disease, congenital heart disease (requiring treatment or with exercise restrictions), , immunodeficiency (primary, acquired, or iatrogenic), a separate episode of pneumonia previously diagnosed within the past 2 weeks, or lung abscess diagnosed within the past six months. Children will not be eligible to participate more than once.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Short-course treatment

    5 days of placebo (after participants already received 3-5 days of antibiotics)

    Drug: Placebo

  • Active comparator
    Standard-duration treatment

    5 days of amoxicillin (after participants already received 3-5 days of antibiotics)

    Drug: Amoxicillin

Interventions

  • DrugPlacebo

    5 days of placebo to be given after 3-5 days of antibiotics

  • Standard-dose amoxicillin (approved by Health Canada) to be given x 5 days.

06

What researchers measure

Primary outcomes

  1. Consent success

    The proportion of potentially eligible participants who consent

    Time frame: Day 0

  2. Open-label antibiotic use

    The proportion of participants who receive open-label (non-study) antibiotics

    Time frame: before Day 30

  3. Losses to followup

    The proportion of participants lost to follow-up

    Time frame: before Day 30

Secondary outcomes

  1. Proportion of participants with late clinical response

    LCR is defined as: i) clinical improvement in fever, work of breathing, oral intake, and activity level, AND ii) lack of receipt of additional antimicrobials

    Time frame: Day 15

  2. Proportion of participants with repeat hospitalization for CAP

    Time frame: before Day 30

  3. Proportion of participants with drug-related AEs (any severity)

    Time frame: before Day 30

  4. Proportion of participants with serious drug AEs

    Time frame: before Day 30

  5. Proportion of participants with unscheduled ED or urgent care visits

    Time frame: before Day 30

  6. Proportion of participants with unscheduled primary care visits

    Time frame: before Day 30

  7. Proportion of participants who develop complicated pneumonia

    Complicated defined by effusion, empyaema, necrotizing pneumonia

    Time frame: before Day 30

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Nov 2025, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2023
First posted
Nov 9, 2023
StartActual
Apr 17, 2024
Primary completionEst.
Nov 30, 2025
CompletionEst.
Jan 1, 2026
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06125340
Lead sponsor
Jeffrey
Responsible party
Jeffrey (Associate Professor, McMaster University) — Sponsor-investigator
First posted
Nov 9, 2023
Start date
Apr 17, 2024
Primary completion
Nov 30, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Dec 12, 2024

Study contacts

Jeffrey Pernica, MD
Contact
pernica@mcmaster.ca
9055212100 ext. 77577
Shamini Selvakumar, MD
Contact
selvaks@mcmaster.ca
9055212100

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion